anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
NEW MATERIAL:A glycoprotein having carcinostatic activity and the following characteristics. Molecular weight, 45,000; protein constitution, composed of alpha-helix and random coil; sugar constitution, composed of beta-polysaccharide; circular dichroic spectrum, having positive peak at 275nm. USE:Carbinostatic agent. PREPARATION:Chlorella (microbial green algae) is extracted with hot water, concentrated at 50 deg.C under reduced pressure, diluted with distilled water, and passed through a semi-permeable membrane to obtain a polymeric fraction which cannot be passed through the membrane. The fraction is adjusted to 5.5pH and hydrolyzed by the addition of a liquid containing alpha-amylase. The hydrolyzed liquid is heated at 80 deg.C to deactivate alpha-amylase, the whole solution is dialyzed, the hydrolyzed sugar is discharged, and the residue is dried under reduced pressure. The dried component is subjected to gel-filtration to obtain the objective glycoprotein component.
FIELD: medicine. SUBSTANCE: method involves per os administering Kamelid S6 preparation 1-2 times a day during 1-1.5 months. Single dose of the preparation depends on body weight. The weight being below 75 kg, 3 grains are given, from 75 to 95 kg, 5 grains are given and 7 grains are given when the weight is greater than 95 kg. EFFECT: accelerated metabolism; delayed muscle-to-fat tissue transformation. 1 cl
No previous studies have investigated the systemic absorption of bupivacaine when used topically for posttonsillectomy pain. The present study was undertaken to investigate the pharmacokinetics of bupivacaine after administration by a swab in the tonsillar fossae over 4 min after tonsillectomy. Eleven adult patients undergoing elective tonsillectomy were recruited. After removal of both tonsils, each of the two tonsillar fossae was covered with a swab moistened with 2 mL of bupivacaine 5 mg/mL, that is, a total of 20 mg bupivacaine. Blood samples were drawn after 0, 5, 10, 20, 30, 45, and 60 min. Bupivacaine was analyzed with an ultra-high-performance liquid chromatography-tandem mass spectrometry method. The highest single measured bupivacaine serum concentration was 23.2 ng/mL and took place 10 min after drug administration. Mean (±SD) Cmax was 11.4 ± 6.0 ng/mL and mean tmax was 11.3 ± 4.7 min. Mean t1/2 was 31.6 ± 9.3 min. As the toxic concentration threshold has been reported to be in the interval 1500-4500 ng/mL, the concentrations measured were well below 2% of the lowest cited toxic threshold. In conclusion, this study shows that applying 4 mL of bupivacaine 5 mg/mL by a swab in the tonsillar fossae posttonsillectomy yields very low plasma concentrations, suggesting its safe application without any risk of systemic toxic effects.
A group of 50 neonates who are clinically well, admitted to the NICU for reasons other than neonatal sepsis or NEC will be recruited into the study to explore the kinetics and concentrations of the panel of biomarkers in healthy subjects comparing to subjects with suspected LONS/NEC. No intervention will be given to the subjects. Blood sampling will be obtained from subjects at 4 time points (Hour 0, 24, 48 and 72) for analysis of the sepsis biomarkers of interest.
Screening period (day 0): normal routine medical sheet and skin care regimen. Intervention days 1, 2, 3, 4, 5: Jefcare Sterile Medical Sheets and skin care regimen.
BACKGROUND: Emotional symptoms are recognized as a key feature in individuals with major depressive disorder. Previously, emotional blunting has been described both as a side effect of antidepressant treatment and as a symptom of depression. Little is known about the change of emotional blunting during antidepressant treatment.
METHODS: The PREDDICT trial is a randomized, placebo-controlled, 6-week trial on the augmentation of vortioxetine with the anti-inflammatory agent celecoxib or placebo. Presently we report on exploratory secondary outcomes of changes in emotional blunting in depression assessed with the Oxford Depression Questionnaire (ODQ) total score and subscores from baseline to 8-week, 3-month, and 6-month follow-up assessments.
RESULTS: In the whole group, there was a significant improvement in the ODQ total score and all subscores after 8 weeks. After stratification of participants into the treatment groups, the ODQ total score as well as subscores related to emotional blunting as a symptom of depression (reduction in positive emotions, not caring) improved between baseline and all follow-up time points in both treatment groups. Changes in subscores considered as a side effect of antidepressants (general reduction in emotions, emotional detachment) were inconclusive in both treatment groups. Overall, the placebo-augmented group showed slightly better results in changes of emotional blunting scores than the celecoxib group as did those with elevated inflammation at screening, regardless of treatment group.
CONCLUSIONS: This analysis suggests favorable effects of vortioxetine on emotional blunting in both short- and long-term course. The beneficial impact of vortioxetine on emotional blunting was weaker in celecoxib-augmented patients compared with placebo, possibly due to pharmacokinetic interactions. Clinical Trials Registration: Australian New Zealand Clinical Trials Registry (ANZCTR), ACTRN12617000527369p. Registered on 11 April 2017, http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12617000527369p.
An oral preparation free from hydrophobic substances comprises ascorbic acid or a physiologically equivalent ascorbate, e.g. ammonium, sodium, potassium, calcium and ferrous ascorbate, and a non-toxic surface active agent.  The surface-active agent may be an organic polymeric non-ionic agent, e.g. polyoxyethylene sorbitan higher fatty acid ester such as the mono-oleate, monolaurate, trioleate, pentaoleate, tetraethyldesoxypolyethylene glycol, alkyloxylpolyethoxyethanol, may be present in amount greater than that of the ascorbic acid.  The preparation may take the form of a digestible capsule containing no more than 200 mg. of ascorbic acid, or an aqueous preparation containing not less than 2 gm. ascorbic acid per 100 ml. such as a clear viscous aqueous solution of pH 6.0 to 7.0 containing 10 to 40 gm. polyoxyethylene sorbitan mono - oleate per 100 ml. of solution, 1 to 30 gm. glycerol and 2 to 20 g,. ascorbic acid per 30 gm. mono-oleate present.  Other substances which may be present are sodium para-aminobenzoate, gentisate or salicylate, citric acid, sodium saccharin, sucrose, caustic soda, sodium benzoate and propionate, flavouring and preserving agents.
The invention relates to the technical field of medicines, in particular to an easily sublimating medicament injection solution and an intravenous injection thereof. Easily sublimating medicaments comprise borneol, camphor, menthol crystal and the like. The injection solution of easily sublimating medicaments mainly consists of the easily sublimating medicaments, a solvent for injection and a small amount of pH regulator. When in use, the easily sublimating medicament intravenous injection can be prepared by uniformly mixing the easily sublimating medicament injection solution with emulsion or a 5 percent glucose injection solution according to a volume ratio of 1:5 to 1:250. After the easily sublimating medicament injection solution is mixed with the emulsion or 5 percent glucose injection solution, a drug loading rate of the easily sublimating medicaments in the intravenous injection can reach 1.5mg/ml and the easily sublimating medicaments cannot be crystallized and separated out in 18 hours. The easily sublimating medicament injection solution has a simple and safe preparation method, high solution stability, is convenient to store and transport and has no toxic or side effects. The difficult problem on clinical application of the injection preparation prepared from the easily sublimating medicaments is solved.
Preliminary findings of our research group indicated that ERA enhances exercise performance (particularly aerobic) after 7-day intake of higher doses of non-selective ERA bosentan (doses used were approved for pulmonary arterial hypertension treatment). This is in part in accordance with results of previous research (Faoro et al. 2009), although authors administered regular single dose (62.5 mg) of bosentan in hypoxic healthy subjects. Our study should examine metabolic profiles of athletes after receiving significantly higher doses of two oral ERA as compared to previous research, along with assessment of ergogenic potential with 8 weeks of administration in placebo-control and randomized design. We expect that ERA will increase time to exhaustion during endurance test, increase the maximal oxygen uptake and rate of ultra-short term heart rate recovery after exercise, and affecting blood and urine cortisol, testosterone and dehydroepiandrosterone following administration. Moreover, we will clearly evaluate 24-h pharmacokinetic profile of ERA in blood and urine and collect data for concentration-time profiles of ERA and main active metabolites, in aim to provide more rationale basis for identification and detection for doping control.
A signal processing method and system combines multi-scale decomposition, such as wavelet, pre-processing together with a compression technique, such as an auto-associative artificial neural network, operating in the multi-scale decomposition domain for signal denoising and extraction. All compressions are performed in the decomposed domain. A reverse decomposition such as an inverse discrete wavelet transform is performed on the combined outputs from all the compression modules to recover a clean signal back in the time domain. A low-cost, non-drug, non-invasive, on-demand therapy braincap system and method are pharmaceutically nonintrusive to the body for the purpose of disease diagnosis, treatment therapy, and direct mind control of external devices and systems. It is based on recognizing abnormal brainwave signatures and intervenes at the earliest moment, using magnetic and/or electric stimulations to reset the brainwaves back to normality. The feedback system is self-regulatory and the treatment stops when the brainwaves return to normal. The braincap contains multiple sensing electrodes and microcoils; the microcoils are pairs of crossed microcoils or 3-axis triple crossed microcoils.
FIELD: medicine, pharmacy. SUBSTANCE: invention describes the novel pharmaceutical composition used for treatment of tumor-bearing animal-host that contains effective amount of β-L-enantiomer of compound of the formula (I)   where R 1  and R 2  are taken among the group including hydrogen atom, acyl-group and C 1 -C 18 -alkyl and f means H or F. Content of corresponding β-D-enantiomer in proposed composition is less 5%. Composition has pharmaceutically acceptable salt of compound in pharmaceutically acceptable carrier. Composition can be used for treatment of patients with tumors including cancer and other states with anomal or unfavorable cell proliferation in animals and humans. EFFECT: enhanced effectiveness of new composition, improved method of synthesis. 49 cl, 5 dwg, 2 tbl, 14 ex
Individuals with a known diagnosis of amyotrophic lateral sclerosis will be recruited from King's College Hospital's Motor Nerve Clinic. The cohort will contain 20 individuals and their study partners and will be part of the study for one year.
The invention relates to the field of anti-cancer and analgesic drugs. The present invention provides compounds useful in the preparation of cancer therapeutics and analgesics. The invention also provides a preparation method of the compound. The synthesis method provided by the invention is simple to operate, has universality and is suitable for batch production. The invention provides application of the compound in preparing a medicament for treating cancer and pain. The medicine prepared by the compound can effectively resist cancers, reduce the dependence on opioid in cancer pain treatment and establish a good pain management mechanism.
The invention relates to a method of making pluripotent stem cells that does not involve the formation of early preimplantation embryos or fetal tissue. The method has general utility in the production of pluripotent stem cells from many mammalian species but has particular application in man where pluripotent stem cell production can be customized to particular human individual. The method involves the fusion of donor somatic or stem cells (or their karyoplasts) with cytoplasmic, membrane-delimited fragments of mammalian oocytes or zygotes. After the initial genomic reprogramming occurs, the cells can proliferate and thus multiply in vitro yielding a large number of autologous cells for cell therapy application. The result of this process is a cell population genomically identical to the somatic, differentiated cells derived from an individual patient. However, these cells are pluripotent in that upon application of specific growth factors, the cells are capable of differentiating into specific cell types as required by the sought clinical indication.
The intervention "Group 1" received the standard feedback report with a one-page summary of the CWC recommendations of interest. Group 1 did not receive any data specific to their prescribing.
Aim 1: Test the feasibility and acceptability of a park-based PA intervention led by Certified Peer Specialists (CPS) and adapted for adults with SMI. Rationale: Park-based interventions led by CPSs represent a novel approach to increase program satisfaction and adherence to PA behavior change in persons with SMI. Hypothesis 1A: Most (80%) people offered the intervention will participate most of the time (≥2 day/week). Hypothesis 1B: CPSs and SMI patients will express satisfaction with the program (6 on an 8-point scale). Aim 2: Test the effectiveness of a park-based PA intervention led by CPSs on increasing PA and improving fitness in adults with SMI. Rationale: Park-based PA is associated with greater intensity and duration of PA, better fitness, and less obesity and depression, issues that are especially problematic for adults with SMI. Hypothesis 2A: People enrolled in the intervention will engage in more PA than at baseline (90min moderate to vigorous PA (MVPA)/week). Hypothesis 2B: The intervention will result in improved fitness (6 min walk test) relative to baseline.
PROBLEM TO BE SOLVED: To obtain a new host cell comprising a cell capable of expressing a human lymphocyte-related cell surface protein LAM-1 having a specific amino acid sequence and useful for the production, etc. of the subject protein capable of improving symptoms due to invasion of lymphocytes into a tissue damaged site, etc. SOLUTION: This surface protein is a new host cell capable of expressing a human lymphocyte-related cell surface protein LAM-1 having an amino acid sequence represented by the formula, with the proviso that one or plural amino acids in the sequence may be substituted, deleted or added so as not to change the bioactivity of the protein and is used for the production, etc. of the LAM-1 useful as a medicinal agent, etc. capable of preventing the evolution of lesions and symptoms due to the migration and invasion of lymphocytes into a tissue damaged site, a taumatic site a tissue transplanted site. The host cell is obtained by transfecting a host cell with an expression system containing a gene capable of encoding the LAM-1 separated from a cDNA population unique to a B cell derived from a human tonsil cDNA library.
If the patient is randomized to the standard arm, the patient will be given intravenous crystalloid fluid (normal saline) as the initial resuscitation fluid with 2 large bore IVs based on the current ATLS guidelines, the standard of care. Subsequent care will proceed per institutional, ATLS guided resuscitation with acute packed red blood cells pRBC administration determined by the hemodynamic response and additional blood component administration guided by rTEG and coagulation panel assessment in conjunction with clinical scenario.
PROBLEM TO BE SOLVED: To obtain such a dental calcined gypsum that maintains the pressure- resistant strength when a resin is implanted, but the resin denture can be easily taken out after the resin is polymerized by heating in a wet state, by adding at least one of succinic acid and/or soluble succinates to a dental calcined gypsum base essentially comprising β-hemihydrate gypsum. SOLUTION: This dental calcined gypsum compsn. consists of 100 pts.wt. of a mixture of β-hemihydrate gypsum between >50 pts.wt. and <=100 pts.wt. and <50 pts.wt. of α-hemihydrate gypsum, to which at least one of succinic acid and/or soluble succinates is added by 0.04 to 0.4 pts.wt. calculated as succinic acid. When the dental calcined gypsum compsn. is used to embed a denture, the compsn. shows no large decrease in wet compressive strength but shows large decrease in the strength after heated in a wet state. The soluble succinate to be compounded is, for example, sodium succinate and potassium succinate.
A method for forming discrete capsules that contain an active agent, such as a pesticide, involves first forming a suspension of the active agent suspended in a solution of an alkali metal silicate such as sodium silicate or a suspension of the active agent suspended in a liquid coacervate resulting from the addition of a coacervation agent such as acetone to the alkali metal silicate solution. The suspension, preferably in the form of droplets formed by ejecting the suspension through an orifice (e.g. a needle), is then contacted with an aqueous solution of a salt such as calcium chloride which reacts with the alkali metal silicate to form an insoluble silicate (e.g., calcium silicate) coating for the active agent while hardening the dispersed active agent in a silicate core matrix. Thus, capsules of the active agent are produced with an insoluble silicate coating. The capsules are maintained in the aqueous salt solution for a sufficient period of time to permit a high degree of conversion of soluble silicate to insoluble silicate. The capsules are then isolated and dried thereby providing structurally intact capsules which act as a free-flow powder. The capsules provide controlled release of the active agent over a prolonged period of time. Methods for preparing such capsules within a three hour period have been devices thereby improving substantially the economics of encapsulating active agents with inorganic coatings. Such brief preparation times are achieved through the use of soluble silicates rich in SiO2 and by increasing the temperature of the aqueous solution of the salt such as calcium chloride to effectively expedite the capsule curing process.
The invention provides traditional Chinese medicine composition used for treating radiation proctitis and a preparation method thereof. The traditional Chinese medicine composition is composed of radix astragali, parched white atractylodes rhizome, radix angelicae sinensis, radix rehmanniae, fried radix paeoniae alba, radix pulsatillae, dandelion, fried smoked plum, elecampane, betel nuts, rhizoma coptidis, and radix glycyrrhizae. On the basis of the formula, the invention provides a medicine formula capable of intensively treating radiation proctitis with a symptom of hematochezia, namely, 20 parts of charred sanguisorba, 10 parts of bletilla striata, 10 parts of setose thistle, and 10 parts of field thistle are added in the traditional Chinese medicine composition. On the basis of the formula, the invention further provides a medicine formula capable of intensively treating radiation proctitis with a symptom of diarrhea, namely, 10 parts of fructus aurantii and 10 parts of Mangnolia Officinalis are added in the traditional Chinese medicine composition. On the basis of the formula, the invention further provides a medicine formula capable of intensively treating radiation proctitis with a symptom of stomachache, namely, 10 parts of rhizoma corydalis and 15 parts of red radix polygoni multiflori are added in the traditional Chinese medicine composition. The traditional Chinese medicine composition has the advantages of being capable of treating radiation proctitis quickly and effectively and is better in therapeutic effect than combination of Chinese traditional medicine and western medicine and pure western medicine.
INTRODUCTION: Differentiated vulvar intraepithelial neoplasia (dVIN) is a high-risk preinvasive vulvar lesion and precursor of human papillomavirus-independent vulvar squamous cell carcinoma (VSCC). Due to its rarity, literature data on its malignant potential are scant. The aim of the study is to assess the risk of developing VSCC in patients surgically treated for dVIN not associated with VSCC (solitary dVIN) and the risk of VSCC recurrence in patients treated for dVIN associated with VSCC (dVIN-VSCC) at first diagnosis.
MATERIAL AND METHODS: A historical cohort study was performed in a northern Italy referral center for vulvar neoplasms. All consecutive women surgically treated for histologically confirmed dVIN from 1994 to 2021 were collected. Primary outcome was cancer risk or recurrent cancer risk, secondary outcomes were risk factors associated with VSCC development or recurrence. Kaplan-Meier method and log-rank test were used to estimate cancer risk or recurrent cancer risk differences and uni- and multivariate Cox regression analyses to identify risk factors associated with VSCC development in solitary dVIN and recurrence of dVIN-VSCC.
RESULTS: Seventy-six patients with dVIN at preoperative biopsy were included: at excisional specimens 44 were solitary dVIN and 32 were dVIN-VSCC. The absolute risk of VSCC development after solitary dVIN treatment was 43.2% with median time to to VSCC diagnosis of 25.4 months (range 3.5-128.0 months). VSCC recurrence absolute risk in treated dVIN-VSCC patients was 31.3% with median time to VSCC recurrence of 52.9 months (range 6.5-94.8 months). At uni- and multivariate regression analyses, only compliant topical ultrapotent corticosteroid treatment after solitary dVIN excision showed an ability to prevent VSCC development. No protective effect by corticosteroid treatment was shown for VSCC recurrence in dVIN-VSCC patients. Smoking was associated with higher cancer recurrence risk in dVIN-VSCC patients on both uni- and multivariate regression analyses.
CONCLUSIONS: Patients with dVIN have a high risk of developing both primary and recurring VSCC. Early recognition, long-term follow up, and compliant ultrapotent topical corticosteroid treatment are recommended.
Collisions of the transcription and replication machineries on the same DNA strand can pose a significant threat to genomic stability. These collisions occur in part due to the formation of RNA-DNA hybrids termed R-loops, in which a newly transcribed RNA molecule hybridizes with the DNA template strand. This study investigated the role of RAD52, a known DNA repair factor, in preventing collisions by directing R-loop formation and resolution. We show that RAD52 deficiency increases R-loop accumulation, exacerbating collisions and resulting in elevated DNA damage. Furthermore, RAD52's ability to interact with the transcription machinery, coupled with its capacity to facilitate R-loop dissolution, highlights its role in preventing collisions. Lastly, we provide evidence of an increased mutational burden from double-strand breaks at conserved R-loop sites in human tumor samples, which is increased in tumors with low RAD52 expression. In summary, this study underscores the importance of RAD52 in orchestrating the balance between replication and transcription processes to prevent collisions and maintain genome stability.